At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 46 target
Drug / intervention
FSRT Stereotactic radiation therapyradiation
Likely dose
Not stated in record
Key inclusion· 14
- ✓Age greater than 18 years
- ✓Performance Status 0 or 1
- ✓1 to 3 brain metastatic lesions (post-metastasectomy or naturally)
- ✓Brain lesions measuring 5-30 mm in diameter
Key exclusion· 15
- ✕Small cell lung cancer, germ cell tumors, lymphoma, leukemia, multiple myeloma
- ✕Concomitant neurodegenerative disease
- ✕Symptoms not attributable to brain metastasis or cancer requiring long-term corticosteroids
- ✕Contraindication to brain MRI or gadolinium injection
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Stereotactic Radiotherapy for Cerebral Metastases with Recent Hemorrhagic Signal: Phase 2 Study in 2 Steps
In Brief
A Phase 2 clinical trial evaluating FSRT Stereotactic radiation therapy for Hemorrhagic Brain Metastases. Currently recruiting, targeting 46 participants across 4 sites.
Detailed Summary
This prospective 2-stage, non-randomized Phase 2 trial evaluates the safety and efficacy of FSRT for the management of hemorrhagic brain metastases
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHemorrhagic Brain Metastases
CountriesFrance
Timeline
Phase 2Recruiting
2019202020212022202320242025202620272028
First PostedOct 2018
Enrollment StartJan 2019
TodayJul 2026
Primary CompletionJun 2027
Study CompletionJan 2028
First PostedOct 5, 2018
Enrollment StartJan 16, 2019
Primary CompletionJun 1, 2027
Study CompletionJan 1, 2028
TodayJul 2, 2026
Enrollment to primary: 8.4 yearsPosted 7.7 years agoPrimary completion in 11 months
Interventions
FSRT Stereotactic radiation therapyradiation
For each metastasis, dose of 30 Gy in 3 fractions at 10 Gy / fraction over 7 days